Biosciences and diagnostics company Enzo Biochem has launched a new RNA gene expression platform called AMPIVIEW.

Powered by the firm’s LoopRNA in situ hybridisation (ISH) technology, the AMPIVIEW platform features products for human papillomavirus (HPV) detection and analysis.

The new platform will help the company expand its presence in the oncology market as well as open the way for it to move into the spatial biology market.

The AMPIVIEW RNA platform brings together the precision of targeted and sequence-particular probes with the sensitivity of the new LoopRNA ISH technology.

The platform’s design facilitates sensitive and specific detection of target genes in tissue or cell samples while ensuring that morphology is preserved.  

HPV testing, which is part of Enzo’s focus on women’s health and oncology, is said to complement the existing offering of the firm’s POLYVIEW immunohistochemistry (IHC) and PATHO-GENE ISH detection platforms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Enzo Biochem stated that the application of the AMPIVIEW visualisation technology to HPV analysis is a ‘logical’ expansion of the company’s existing wide portfolio of tissue analysis assays and reagents.

Enzo Biochem CEO Hamid Erfanian said: “Our outstanding team of scientists at Enzo developed the new LoopRNA ISH technology with clinical pathology in mind.

“The AMPIVIEW RNA platform is flexible and adaptable, with established manual or automated workflows. This product will support the advancement of drug discovery and development and help close the spatial biology gap in clinical pathology.”

Enzo Biochem is a provider of molecular diagnostics that mainly focuses on the development of advanced diagnostic platform technologies.